{"corpus_id":249828536,"paper_sha":"9a7a6bcd3b9e3c2afe4ae36d12018c0b4fdade5f","doi":"10.3389/fneur.2022.885218","arxiv_id":null,"pmid":35785363,"pmcid":"9247462","mag_id":null,"dblp_id":null,"acl_id":null,"title":"Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management","year":2022,"publication_date":"2022-06-17","venue":"Frontiers in Neurology","journal":{"name":"Frontiers in Neurology","pages":null,"volume":"13"},"journal_issn":null,"journal_title":null,"publication_types":["Review","JournalArticle"],"pubmed_pub_types":["Journal Article","Review"],"s2_fields_of_study":["Medicine"],"reference_count":207,"citation_count":239,"influential_citation_count":14,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":null,"chemicals":null,"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"https://www.frontiersin.org/articles/10.3389/fneur.2022.885218/pdf","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/9a7a6bcd3b9e3c2afe4ae36d12018c0b4fdade5f","s2_open_access_license":"CCBY","s2_open_access_status":"GOLD","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is the most recently defined inflammatory demyelinating disease of the central nervous system (CNS). Over the last decade, several studies have helped delineate the characteristic clinical-MRI phenotypes of the disease, allowing distinction from aquaporin-4 (AQP4)-IgG-positive neuromyelitis optica spectrum disorder (AQP4-IgG+NMOSD) and multiple sclerosis (MS). The clinical manifestations of MOGAD are heterogeneous, ranging from isolated optic neuritis or myelitis to multifocal CNS demyelination often in the form of acute disseminated encephalomyelitis (ADEM), or cortical encephalitis. A relapsing course is observed in approximately 50% of patients. Characteristic MRI features have been described that increase the diagnostic suspicion (e.g., perineural optic nerve enhancement, spinal cord H-sign, T2-lesion resolution over time) and help discriminate from MS and AQP4+NMOSD, despite some overlap. The detection of MOG-IgG in the serum (and sometimes CSF) confirms the diagnosis in patients with compatible clinical-MRI phenotypes, but false positive results are occasionally encountered, especially with indiscriminate testing of large unselected populations. The type of cell-based assay used to evaluate for MOG-IgG (fixed vs. live) and antibody end-titer (low vs. high) can influence the likelihood of MOGAD diagnosis. International consensus diagnostic criteria for MOGAD are currently being compiled and will assist in clinical diagnosis and be useful for enrolment in clinical trials. Although randomized controlled trials are lacking, MOGAD acute attacks appear to be very responsive to high dose steroids and plasma exchange may be considered in refractory cases. Attack-prevention treatments also lack class-I data and empiric maintenance treatment is generally reserved for relapsing cases or patients with severe residual disability after the presenting attack. A variety of empiric steroid-sparing immunosuppressants can be considered and may be efficacious based on retrospective or prospective observational studies but prospective randomized placebo-controlled trials are needed to better guide treatment. In summary, this article will review our rapidly evolving understanding of MOGAD diagnosis and management.","claims":[{"public_id":"cl_224024d88797c6f8bc7b4fe294369cc6","status":"active","text":"A relapsing course occurs in approximately 50% of patients.","confidence":0.94,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_224024d88797c6f8bc7b4fe294369cc6"},{"public_id":"cl_cc4e54427a548cb9b26d4ee24c5b9a1c","status":"active","text":"Clinical manifestations are heterogeneous, ranging from isolated optic neuritis or myelitis to multifocal CNS demyelination, acute disseminated encephalomyelitis, or cortical encephalitis.","confidence":0.98,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_cc4e54427a548cb9b26d4ee24c5b9a1c"},{"public_id":"cl_6fa5e87ce5a735b59ae1fd267f91791f","status":"active","text":"High-dose steroids are effective for acute attacks, plasma exchange may be considered for refractory cases, and empiric maintenance immunosuppression is generally reserved for relapsing disease or severe residual disability.","confidence":0.92,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_6fa5e87ce5a735b59ae1fd267f91791f"},{"public_id":"cl_c4a8e5b8e59e6c13cdae51107b270f80","status":"active","text":"MOGAD has characteristic clinical-MRI phenotypes that help distinguish it from AQP4-IgG+NMOSD and multiple sclerosis.","confidence":0.96,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_c4a8e5b8e59e6c13cdae51107b270f80"},{"public_id":"cl_f86d897e4332c839374d7a8ec7aff184","status":"active","text":"Perineural optic nerve enhancement, the spinal cord H-sign, and T2-lesion resolution over time are MRI features that increase diagnostic suspicion and help discriminate MOGAD from MS and AQP4+NMOSD.","confidence":0.97,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_f86d897e4332c839374d7a8ec7aff184"},{"public_id":"cl_d99fff4f746e34c47e0006d1a8a54ad1","status":"active","text":"Serum MOG-IgG, and sometimes CSF MOG-IgG, confirms the diagnosis in patients with compatible clinical-MRI phenotypes, but false positives can occur, especially with indiscriminate testing of unselected populations.","confidence":0.95,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_d99fff4f746e34c47e0006d1a8a54ad1"}],"concepts":[{"public_id":"co_0108f7ee95deb5638b52cff1e02aef0c","status":"active","name":"clinical-MRI phenotypes","description":"The combined clinical and magnetic resonance imaging patterns used to characterize the disease presentation.","types":["phenotype"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_0108f7ee95deb5638b52cff1e02aef0c"},{"public_id":"co_16a0d2ea258c8c41fd64a45e67ace2ce","status":"active","name":"perineural optic nerve enhancement","description":"MRI enhancement around the optic nerve that is described as a characteristic imaging feature.","types":["MRI feature"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_16a0d2ea258c8c41fd64a45e67ace2ce"},{"public_id":"co_30ce035610156bd8441ef87bddb5ef37","status":"active","name":"relapsing course","description":"A disease pattern in which attacks recur over time after initial presentation.","types":["disease course"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_30ce035610156bd8441ef87bddb5ef37"},{"public_id":"co_64f46df8f50c30552c84cb4748d25e55","status":"active","name":"high dose steroids","description":"High-dose corticosteroid treatment used for acute disease attacks.","types":["treatment"],"aliases":["high-dose steroids"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_64f46df8f50c30552c84cb4748d25e55"},{"public_id":"co_84fcf7359e25fc31d4c652b6eaa92e74","status":"active","name":"AQP4-IgG+NMOSD","description":"Aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder, a demyelinating disease used as a comparator diagnosis.","types":["disease"],"aliases":["aquaporin-4 (AQP4)-IgG-positive neuromyelitis optica spectrum disorder"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_84fcf7359e25fc31d4c652b6eaa92e74"},{"public_id":"co_ac9214d4c2f5745973d576d2fdf0c4ca","status":"active","name":"CSF","description":"Cerebrospinal fluid, a specimen that can also contain detectable MOG-IgG.","types":["specimen"],"aliases":["cerebrospinal fluid"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_ac9214d4c2f5745973d576d2fdf0c4ca"},{"public_id":"co_c3f98b62005384850a35113fe2709c2e","status":"active","name":"spinal cord H-sign","description":"An MRI pattern in the spinal cord described as a characteristic diagnostic feature.","types":["MRI feature"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_c3f98b62005384850a35113fe2709c2e"},{"public_id":"co_c86d8440f8e6adf29b1d06a3246c0924","status":"active","name":"acute disseminated encephalomyelitis","description":"A multifocal inflammatory demyelinating syndrome affecting the central nervous system.","types":["condition"],"aliases":["ADEM"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_c86d8440f8e6adf29b1d06a3246c0924"},{"public_id":"co_cba08ebbdbdf590f009838103ea98a66","status":"active","name":"maintenance treatment","description":"Ongoing preventive therapy used to reduce future disease attacks.","types":["treatment"],"aliases":["attack-prevention treatment"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_cba08ebbdbdf590f009838103ea98a66"},{"public_id":"co_d1af04cf2fdd8cdf3ef9eeb13258ab14","status":"active","name":"serum","description":"Blood-derived liquid used here as the main specimen for antibody detection.","types":["specimen"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_d1af04cf2fdd8cdf3ef9eeb13258ab14"},{"public_id":"co_daba63c49c16a0f8a12477f950746a72","status":"active","name":"plasma exchange","description":"A blood purification therapy considered for refractory acute attacks.","types":["treatment"],"aliases":["plasmapheresis"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_daba63c49c16a0f8a12477f950746a72"},{"public_id":"co_e084c6d4af90534baded51219f69147b","status":"active","name":"optic neuritis","description":"Inflammation of the optic nerve causing visual symptoms.","types":["condition"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_e084c6d4af90534baded51219f69147b"},{"public_id":"co_eba0ce7117ace30f35329b5395dbff5b","status":"active","name":"MOGAD","description":"Myelin oligodendrocyte glycoprotein antibody-associated disease, an inflammatory demyelinating disorder of the central nervous system.","types":["disease"],"aliases":["myelin oligodendrocyte glycoprotein antibody-associated disease"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_eba0ce7117ace30f35329b5395dbff5b"},{"public_id":"co_f4016253aa5b2982802fe5e74edd1668","status":"active","name":"T2-lesion resolution over time","description":"The tendency for T2 MRI lesions to diminish or resolve on follow-up imaging.","types":["MRI feature"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_f4016253aa5b2982802fe5e74edd1668"},{"public_id":"co_f938b9c921a9e7138b710c80a9d3a61b","status":"active","name":"MOG-IgG","description":"Antibodies against myelin oligodendrocyte glycoprotein measured in serum or cerebrospinal fluid.","types":["biomarker"],"aliases":["MOG antibody"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_f938b9c921a9e7138b710c80a9d3a61b"}],"external_ids":{"DOI":"10.3389/fneur.2022.885218","ArXiv":null,"PubMed":35785363,"PubMedCentral":"9247462","MAG":null,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"https://www.frontiersin.org/articles/10.3389/fneur.2022.885218/pdf","landing_url":"https://www.semanticscholar.org/paper/9a7a6bcd3b9e3c2afe4ae36d12018c0b4fdade5f","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":"CCBY","status":"GOLD","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":631616,"paper_uid":"5e124604-e904-480b-a41d-986fc7fc76ef","canonical_identity":{"paper_id":631616,"paper_uid":"5e124604-e904-480b-a41d-986fc7fc76ef","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/249828536"}